Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
CardieX ( (AU:CDX) ) has issued an update.
CardieX reported strong growth in sales of its Pulse arterial health monitor, with consumer and institutional demand driving sales to over A$0.7 million and more than 2,100 units sold in FY25. The company is optimizing its marketing strategy to support sustainable growth and improve customer acquisition. The Pulse has received positive feedback for its clinical utility and usability, with cardiologists incorporating its data into treatment plans. The launch of On-Demand Assessments in the CONNEQT App has increased user engagement, supporting a transition to subscription-based digital health services. The company also completed a $6.5 million placement and entitlement offer, positioning itself for future growth.
More about CardieX
CardieX operates in the health technology industry, focusing on cardiovascular health monitoring solutions. Their primary products include the Pulse arterial health monitor and the CONNEQT App, which provide clinical-grade insights and digital health services. The company targets both consumers and healthcare professionals, aiming to enhance patient care and engagement through innovative health monitoring technologies.
Average Trading Volume: 370,445
Technical Sentiment Signal: Sell
Current Market Cap: A$19.25M
See more insights into CDX stock on TipRanks’ Stock Analysis page.